Lipid profile of patients with arterial hypertension who underwent COVID-19: possibilities of drug therapy/ LEADER
| Autor: | I. A. Zolotovskaya, V. P. Kuzmin, O. A. Rubanenko, P. R. Shatskaya, A. S. Salasyuk |
|---|---|
| Jazyk: | English<br />Russian |
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Рациональная фармакотерапия в кардиологии, Vol 18, Iss 3, Pp 282-288 (2022) |
| Druh dokumentu: | article |
| ISSN: | 1819-6446 2225-3653 |
| DOI: | 10.20996/1819-6446-2022-06-08 |
| Popis: | Aim. To study the dynamics of the lipid profile of hypertensive patients with dyslipidemia who underwent COVID-19.Material and methods. Hypertensive patients with dyslipidemia who underwent COVID-19 [n=126; 58 men and 68 women; median age 60 (56.0; 65.5) years] examined. Patients were included into two groups: group 1 (n=64) received a single pill combination of lisinopril + amlodipine + rosuvastatin; 2 groups (n=62) continued the previous drug treatment. Clinical, demographic, office blood pressure (BP), total cholesterol (TC), low density lipoprotein cholesterol (LDL-c), high density lipoprotein cholesterol, triglycerides, C-reactive protein (CRP) levels were assessed in all patients in 3 visits within 24 weeks.Results. The groups did not differ in prior antihypertensive therapy (except for more frequent use of angiotensin II receptor blockers in group 2, p |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|